Leerink Swann initiates coverage on Syneron Medical (Nasdaq: ELOS) with an Outperform rating.

Leerink analyst says, "We believe Syneron's deal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE